Company: MIRA
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001183
Chunk: 1542

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 15
Chunk 1542
---
558,097 

    Stockholders’
    Equity 

    Preferred
    Stock, $0.0001 par value, 10,000,000 shares authorized and none issued or outstanding. 
     -  
     - 
  
    Common
    Stock, $0.0001 par value; 100,000,000 shares authorized, 16,560,852 and 14,780,885 shares issued and outstanding at December 31,
    2024 and December 31, 2023, respectively. 
     1,656  
     1,478 
  
    Additional
    paid-in capital 
     31,335,815  
     25,657,930 
  
    Accumulated
    deficit 
     (29,137,721) 
     (21,285,062)
  
    Total
    stockholders’ equity 
     2,199,750  
     4,374,346 
  
    Total
    liabilities and stockholders’ equity 
    $2,923,099  
    $4,932,443 

See
notes to consolidated financial statements

F-4

MIRA
PHARMACEUTICALS, INC.

STATEMENTS
OF OPERATIONS

    2024  
    2023 

    Year
    Ended December 31, 

    2024  
    2023 
  
    Revenues 
    $-  
    $- 

    Operating
    costs: 

    General
    and administrative expenses 
     4,712,753  
     6,499,537 
  
    Related
    party travel costs 
     -  
     453,550 
  
    Research
    and development expenses 
     3,305,575  
     1,572,962 
  
    Total
    operating costs 
     8,018,328  
     8,526,049 

    Interest
    income (expense), net 
     165,669  
     (3,456,294)
  
    Net
    loss attributable to common stockholders 
    $(7,852,659) 
    $(11,982,343)
  
    Basic
    and diluted loss per share 
    $(0.51) 
    $(0.85)
  
    Basic
    weighted average common stock shares outstanding